The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution

Sequential ipilimumab (Ipi) versus best supportive care (BSC) following first-line chemotherapy (Ctx) in patients (pts) with unresectable locally advanced or metastatic gastric or gastro-esophageal junction (GEJ) cancer: A randomized, open-label, two-arm, phase II trial (CA184-162) of immunotherapy as a maintenance concept.

Markus Hermann Moehler

Consultant or Advisory Role - Bristol-Myers Squibb

Yeul Hong Kim

Research Funding - Bristol-Myers Squibb

Iain B. Tan

No relevant relationships to disclose

Agnes Balogh

Employment or Leadership Position - Bristol-Myers Squibb

Teresa Kong Sanchez

Employment or Leadership Position - Bristol-Myers Squibb

Stock Ownership - Bristol-Myers Squibb

Yung-Jue Bang

Consultant or Advisory Role - Bristol-Myers Squibb (U)

Research Funding - Bristol-Myers Squibb